Suppr超能文献

为一名接受慢性血液透析的肝硬化患者进行可行的孤立性肝移植。

Feasible isolated liver transplantation for a cirrhotic patient on chronic hemodialysis.

作者信息

Morita Kazutoyo, Shirabe Ken, Yoshizumi Tomoharu, Ikegami Toru, Masuda Toshiro, Hashimoto Naotaka, Mano Yohei, Miyata Tatsunori, Soejima Yuji, Maehara Yoshihiko

机构信息

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

Case Rep Gastroenterol. 2013 Jul 18;7(2):299-303. doi: 10.1159/000354140. Print 2013 May.

Abstract

End-stage liver and kidney disease (ELKD) is an indication for deceased donor simultaneous liver-kidney transplantation. Although a few cases of living donor liver-kidney transplantation have been reported, the invasiveness remains to be discussed. Living donor liver transplantation (LDLT) is an alternative choice for ELKD, but has never been reported. Here, we report a case of successful LDLT for a patient with ELKD on hemodialysis. The patient was a 63-year-old male and had decompensated hepatitis C cirrhosis with seronegativity for hepatitis C virus. He had non-diabetic end-stage renal failure and had been on hemodialysis for 3 years. He was in good general condition except for hepatic and renal failure. The living donor was his 58-year-old healthy wife. A right lobe graft was transplanted to the recipient under continuous hemodiafiltration (CHDF) and extracorporeal veno-venous bypass. CHDF was continued until postoperative day 4, at which point CHDF was converted to hemodialysis. His posttransplant course was good and he was discharged on postoperative day 36. To the best of our knowledge, this is the first report of LDLT for a patient on chronic hemodialysis. Therefore, being on hemodialysis is not a contraindication for LDLT. LDLT is feasible for a patient with ELKD on hemodialysis.

摘要

终末期肝肾疾病(ELKD)是尸体供体肝肾联合移植的适应证。虽然已有少数活体供体肝肾移植的病例报道,但手术的侵袭性仍有待探讨。活体供体肝移植(LDLT)是ELKD的一种替代选择,但此前从未有过相关报道。在此,我们报告一例为正在接受血液透析的ELKD患者成功实施LDLT的病例。该患者为一名63岁男性,患有失代偿期丙型肝炎肝硬化,丙型肝炎病毒血清学检测呈阴性。他患有非糖尿病性终末期肾衰竭,已接受血液透析3年。除肝肾功能衰竭外,他的一般状况良好。活体供体是他58岁的健康妻子。在持续血液透析滤过(CHDF)和体外静脉 - 静脉旁路支持下,将右叶移植肝植入受体。CHDF持续至术后第4天,之后CHDF转换为血液透析。他的移植后过程顺利,术后第36天出院。据我们所知,这是首例为慢性血液透析患者实施LDLT的报道。因此,接受血液透析并非LDLT的禁忌证。对于正在接受血液透析的ELKD患者,LDLT是可行的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a82b/3728599/047d3d340839/crg-0007-0299-g01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验